Survodutide
ResearchA dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim researched for obesity and NASH (non-alcoholic steatohepatitis / liver fat disease).
Weight ManagementMetabolic HealthGLP-1 Agonist
Half Life
~7 days
Time to Results
4-12 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyOnce weekly
Cost$$$
🐾 Griffin Says...
Survodutide is particularly interesting for NASH research - fatty liver disease is a massive growing health problem. The dual GLP-1 and glucagon action is specifically helpful for liver fat reduction, which GLP-1 alone handles less effectively.
Benefits
- Weight reduction
- Liver fat reduction (NASH research)
- Metabolic improvement
- Appetite suppression
Best For
- Weight management research
- Liver disease research
- Metabolic health
Body Systems
MetabolicLiverEndocrine
Mechanisms of Action
- Dual GLP-1 and glucagon agonism
- Glucagon receptor enhances fat burning
- GLP-1 reduces appetite
- Both pathways improve liver metabolism
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Common | Mild |
| Vomiting | Uncommon | Mild |
Contraindications
Similar to other GLP-1 agonists
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator